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Abstract The field of the biology of ageing has
received increasing attention from a biomedical point
of view over the past decades. The main reason has
been the realisation that increases in human population
life expectancy are accompanied by late onset dis-
eases. Indeed, ageing is the most important risk factor
for a number of neoplastic, neurodegenerative and
metabolic pathologies. Advances in the knowledge of
the genetics of ageing, mainly through research in
model organisms, have implicated various cellular
processes and the respective signalling pathways that
regulate them in cellular and organismal ageing.
Associated with ageing is a dysregulation of metabolic
homeostasis usually manifested as age-related obesity,
diminished insulin sensitivity and impaired glucose
and lipid homeostasis. Metabolic deterioration con-
tributes to the ageing phenotype and metabolic
pathologies are thought to be one of the main factors
limiting the potential for lifespan extension. Great
efforts have been directed towards identifying phar-
macological interventions with the potential to
improve healthspan and a number of natural and
synthetic compounds have shown promise in achiev-
ing beneficial metabolic effects.
Keywords Ageing  PI3K  Insulin resistance 
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Introduction
Cell signalling pathways process cues from the
extracellular environment and signals of cellular
status to ensure cells respond appropriately to
maintain their homeostasis. Metabolic homeostasis
is a key component of cellular and organismal
homeostasis. In multicellular organisms, metabolic
homeostasis requires the coordinate response of
distinct cell and tissue types. Cell signalling path-
ways that sense the availability of nutrients and the
energy status of the cells communicate with hor-
monal and growth factor signalling pathways to co-
ordinately regulate whole body metabolic homeosta-
sis. Ageing results in gradual deterioration of
various cellular functions including of metabolic
regulation. The age-related decline in metabolic
homeostasis is likely an important contributing
factor to general organismal ageing, as a number
of interventions, genetic and pharmacological,
affecting the activity of metabolic pathways also
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affect the rate of ageing. Indeed, the Insulin/IGF-1
Signalling (IIS) pathway and the mechanistic Target
Of Rapamycin (mTOR) pathway are the most
extensively studied pathways shown to regulate
lifespan and healthspan in a number of model
organisms (Fontana et al. 2010; Kenyon 2010).
Moreover, calorie restriction, the most potent envi-
ronmental intervention shown to extend lifespan and
healthspan in a number of species, is accompanied
by alterations in the insulin/IGF-1 circulating levels,
whereas inhibition of the mTOR pathway has been
shown to have both common and distinct effects
with calorie restriction (Kaeberlein and Kennedy
2009; Miller et al. 2014).
The relationship between ageing and metabolic
regulation is bidirectional: Ageing impairs the activ-
ity of key metabolic signalling pathways and the
ensuing metabolic dysregulation results in acceler-
ated ageing. For example, age-related impairment in
the activity of the insulin signalling pathway results
in insulin resistance. The ensuing hyperglycemia, as
a result of dysregulated glucose clearance, promotes
formation of advanced glycation end products
(AGEs), which in turn cause tissue damage further
exacerbating metabolic dysregulation and accelerat-
ing the organismal ageing process (Semba et al.
2010).
The finding that loss-of-function mutations in genes
encoding components of the IIS pathway can improve
health span and in many cases the metabolic profile of
aged mice is seemingly paradoxical (Barzilai et al.
2012). Various potential mechanisms have been
proposed to explain this phenomenon. An important
implication of these findings is that pharmacological
targeting of metabolic signalling pathways can pro-
duce beneficial metabolic effects and ameliorate age-
related metabolic pathologies. The activity of cell
signalling pathways can readily be manipulated, as a
large number of their component molecules are
enzymes such as kinases and phosphatases, which
can be inhibited or activated with the use of natural or
synthetic compounds.
Here we summarise some key findings on the role
of signalling pathways in metabolic homeostasis over
the course of ageing, generated mainly through
research in model organisms, and the evidence
supporting pharmacological manipulation of these
pathways as a means to improve metabolic health at
old age.
Calorie restriction in lifespan and healthspan
Calorie restriction is the most potent environmental
intervention known to increase lifespan and health-
span in a number of species including primates
(Colman et al. 2014). The molecular mechanisms
underlying the beneficial effects of calorie restriction
on lifespan and healthspan have been extensively
studied and debated over the years (Masoro 2009).
Various mechanisms have been proposed to explain
the effects of calorie restriction ranging from
enhanced stress resistance and improved proteostasis
(Mitchell et al. 2016) to reduced inflammation (Chung
et al. 2002). With regards to metabolic effects, calorie
restricted animals are normally leaner and more
insulin sensitive and glucose tolerant than ad libitum
fed animals. It has recently been reported that calorie
restriction induces browning of the adipose tissue with
profound beneficial metabolic consequences (Fab-
biano et al. 2016). Also calorie restriction was recently
reported to protect from accelerated ageing induced by
DNA-repair deficiency (Vermeij et al. 2016). Signif-
icant progress has been made in the identification of
the signalling pathways mediating the effects of
calorie restriction (Fig. 1). Growth factor, energy
and nutrient sensing pathways likely have a prominent
Fig. 1 Signalling pathways implicated in age-related metabolic
decline. Calorie restriction is the most potent environmental
intervention that improves the metabolic profile and extends
healthspan and lifespan of various animal species. Calorie
restriction is thought to be suppressing the GH/IGF-1, insulin/
PI3K, and mTOR pathways and activating the AMPK pathway.
These pathways provide potential targets for therapeutic
intervention to improve metabolic homeostasis at old age.
Pointed arrows indicate activatory and blunt arrows inhibitory
actions
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role in mediating the effects of calorie restriction
(Anderson and Weindruch 2010; Lopez-Lluch and
Navas 2016). The fact that circulating IGF-1 and
insulin levels in calorie restricted animals are lower
than those in ad libitum fed ones (Argentino et al.
2005; Huffman et al. 2008; Weiss et al. 2006) has
pointed to a potential role for the somatotropic
(Growth Hormone (GH)/IGF-1) axis and the IIS
pathways in the mediation of the effects of calorie
restriction. Genetic evidence has lent further support
for a role of somatotropic signalling (Bonkowski et al.
2006). Also, the mTOR and AMP-activated protein
kinase (AMPK) pathways together with sirtuins, a
family of NAD-dependent deacetylases have also b-
een implicated as effectors of the benefits associated
with calorie restriction. In line with genetic studies,
unbiased gene expression analyses in tissues of calorie
restricted animals have revealed that genes encoding
components of the somatotropic and the IIS pathways
as well as genes involved in metabolic processes and
energy metabolism are consistently part of the
molecular signature of calorie restriction (Plank
et al. 2012). Therefore, pharmacological agents
targeting components of these pathways might have
the potential to mimic the beneficial effects of calorie
restriction. The field of calorie restriction mimetic
compounds has been an area of intensive research, as it
holds great promise for therapeutic applications in the
combat against age-related diseases. Below, we briefly
summarise the key evidence implicating these cell
signalling pathways in lifespan and healthspan exten-
sion and we discuss the progress in pharmacological
targeting of these pathways with a focus on improve-
ments in metabolic homeostasis.
Growth factor, energy and nutrient sensing
pathways in metabolic regulation and ageing
The main cell signalling pathways that have been
implicated in the modulation of the rate of ageing have
at the same time important roles in metabolic regula-
tion. These are the somatotropic axis, insulin/IGF-1,
mTOR and AMPK signalling pathways. These path-
ways are interlinked to ensure coordinate regulation
and fine-tuning of cellular metabolic responses in line
with cellular energy status, nutrient availability and
hormonal/growth factor signalling input (Fig. 2).
Feedback loops operate within the pathways to
regulate signal intensity and duration. A key feedback
mechanism for downregulation of IIS involves phos-
phorylation of the Insulin Receptor Substrates (IRS)
by p70 ribosomal protein S6-kinase-1 (S6K1) follow-
ing activation of mTOR (Harrington et al. 2004; Shah
et al. 2004). In fact, sustained activation of S6K1 and
various other stress-induced serine/threonine kinases
is thought to be a major cellular mechanism in the
development of insulin resistance (Tanti and Jager
2009). Key mediators of the metabolic effects of the
IIS pathway are Phosphoinositide 3-Kinase (PI3K)
and its downstream effectors, serine/threonine kinase
Akt and FOXO transcription factors (Whiteman et al.
2002). FOXO transcription factors are essential
mediators of the lifespan extending effects of IIS
attenuation (Martins et al. 2016). Consistent with this,
the gene encoding FOXO3 is one of few human genes
consistently associated with longevity in a number of
distinct populations (Morris et al. 2015). FOXO
transcription factors have multiple metabolic effects.
Notably, FOXO1 plays an essential role in the
regulation of hepatic glucose production (Gross et al.
2008). mTOR’s most extensively studied role is in the
regulation of protein translation. mTOR key effectors
in this process are the above mentioned S6K1 and the
translational repressor eIF4E-Binding Protein 1
(4EBP1). mTOR has also prominent roles in lipid
biosynthesis (Caron et al. 2015).
Closely intertwined with the IIS and mTOR path-
ways is the Liver Kinase B (LKB) 1/AMPK pathway,
which plays a role in energy status sensing (Garcia and
Shaw 2017). Overexpression of one of the AMPK
subunits has been shown to increase lifespan in C.
elegans (Apfeld et al. 2004). AMPK activation brings
about beneficial metabolic effects mainly by promot-
ing glucose uptake and fatty acid oxidation. AMPK
activation is thought to mediate the effects of the anti-
diabetic biguanide drug metformin at least in part, as
additional mechanisms have been shown to underlie
metformin’s effects in the liver; notably suppression
of gluconeogenesis through inhibition of mitochon-
drial glycerophosphate dehydrogenase (Madiraju et al.
2014) and antagonism of glucagon action through
accumulation of AMP and consequent inhibition of
adenylyl cyclase (Miller et al. 2013).
The Ras/Extracellular Signal Regulated Kinase
(ERK) pathway is an essential pathway in transmis-
sion of mitogenic signalling, which is also activated
downstream the insulin/IGF-1 receptor via IRS. The
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Ras/ERK pathway has also been implicated in the
modulation of lifespan (Slack 2017). It has recently
been reported that administration of trametinib, an
inhibitor of ERK activation, extends the lifespan of D.
melanogaster (Slack et al. 2015). A key downstream
effector of the pathway in lifespan extension is AOP, a
transcriptional repressor of the ETS family. Whether a
similar lifespan extending effect of ERK inhibition
could be attainable in mammalian species remains to
be seen. Evidence for metabolic effects of Ras/ERK
pathway perturbations, at least under obesogenic
conditions, has been presented before and it is
summarised in (Slack 2017). However, the potential
metabolic effects of long-term administration of this
inhibitor in mammalian species also remain to be seen.
The somatotropic, insulin/IGF-1 and mTOR sig-
nalling pathways have been extensively studied in the
context of ageing and age-related metabolic home-
ostasis over the years and they are discussed below in
more detail, together with the role of sirtuins, a class of
histone deacetylases, which have emerged as impor-
tant regulators of cellular energy homeostasis.
Somatotropic signalling in ageing and metabolism
Signalling via the growth hormone/insulin-like growth
factor-1 (GH/IGF-1) axis, known as the somatotropic
axis, is essential for body growth. IGF-1 is produced
by the liver upon stimulation by GH released from the
anterior pituitary gland. Loss-of-function mutations in
components of the somatotropic axis have been shown
to affect longevity in mammals (Junnila et al. 2013). A
number of mouse mutants with spontaneous or
targeted loss-of-function mutations that diminish
production or impair sensing of GH have been
described (Brown-Borg 2015). All these mutants have
smaller body size and substantially extended lifespan.
The first group of this type of mutants to be studied
were hypopituitary mice, such as Snell and Ames
dwarf mice which bear the Pit-1dw and the Prop-1df
Fig. 2 Interrelationships between growth factor, nutrient avail-
ability and energy sensing pathways in metabolic regulation in
health. The Ras/ERK and PI3K/Akt pathways are activated
upon insulin/IGF1 stimulation. Akt, a key effector of insulin/
PI3K signalling mediates most of the metabolic actions of
insulin, notably stimulation of glucose uptake and glycogen
synthesis and inhibition of lipolysis. The mTOR pathway
integrates signals from growth factor stimulation (via Akt),
aminoacid availability and energy status (via AMPK). mTOR-
activated S6K1 is a key component of a feedback loop that
downregulates insulin’s signal. FOXO transcription factors,
which upon phosphorylation by Akt are inhibited through
nuclear exclusion, also have metabolic roles, prominently in the
regulation of gluconeogenesis. AMPK is activated by low
energy (high AMP/ATP and/or ADP/ATP ratio) stress via
phosphorylation by LKB1 and promotes glucose uptake and
fatty acid oxidation. The majority of the molecular components
of these pathways have been omitted from the schematic for
simplicity
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(Prophet of Pit-1) gene mutations, respectively. Both
mutations affect the activity of the Pit-1 transcription
factor, which is required for proper development of the
anterior pituitary gland. Both Snell and Ames mice
exhibit a deficiency in release of pituitary hormones
(growth hormone, thyroid stimulating hormone and
prolactin), greatly reduced body size, reduced fertility,
increased adiposity, undetectable circulating IGF-1,
and low insulin and glucose levels. The other group of
somatotropic axis mutants consists of GH-resistant
mice, specifically GH receptor and GH-binding pro-
tein (GHR/BP) knockout mouse (Laron mouse) (Zhou
et al. 1997) as well as GH-deficient mice, due to a
spontaneous mutation (little mice) or targeted disrup-
tion of the Ghrhr gene (GHRH-KO), which encodes
the GH-releasing hormone receptor (Alba and Salva-
tori 2004; Godfrey et al. 1993). Hypopituitary dwarf
mice display a 40–70% increase in mean lifespan
depending on the specific mutation and sex (Brown-
Borg et al. 1996; Flurkey et al. 2001). Even though
these mutant mice are deficient in other hormones in
addition to GH, their lifespan extension seems to be
primarily due to GH deficiency, as the lifespan of
Ames dwarf mice treated with GH reverts back to that
of control animals (Panici et al. 2010).
Hypopituitary, GH deficient and GH resistant mice
have been extensively characterised with respect to
their metabolic phenotypes, over the years (Bartke and
Westbrook 2012). Ames mice, as wells as GHR-KO
mice, display increased adiposity, hypoinsulinemia
and hypoglycaemia, increased adiponectin levels and
reduced serum lipids. Interestingly, visceral fat from
GHR-KO mice has been shown to produce higher
levels of adiponectin, which likely explains the
improved insulin sensitivity and glucose tolerance in
the face of increased adiposity (List et al. 2011).
Indeed removal of visceral fat from GHR-KO mice
resulted in reduced insulin sensitivity in contrast to
wild type mice, in which the same intervention
improved insulin sensitivity (Masternak et al. 2012).
Furthermore, indirect calorimetry experiments
revealed increased oxygen consumption and reduced
respiratory quotient indicating that these mutants have
elevated oxidative metabolism and preferentially
utilise lipids as fuel (Westbrook et al. 2009). Such
properties can explain the beneficial metabolic param-
eters, i.e. improved insulin sensitivity and glucose
homeostasis of these dwarf mutants. Interestingly,
increased respiration was evident only under standard
vivarium temperature (commonly 23 C) whereas
under mouse thermoneutral conditions (30 C) there
was no difference (Bartke and Westbrook 2012). This
suggests that the small body size of these mutants
could be the key determinant of their metabolic
phenotype, as it necessitates an increased metabolic
rate in order to maintain body temperature.
The extent to which reduction in the IGF-1 accounts
for the life extending effects of GH-deficient and GH-
resistant mice is not fully clear, but both GH-deficient
and GH-resistant mice consistently show more robust
lifespan extension than IGF-1-deficient mice (Bartke
2009). Gene inactivation of the IGF-1 receptor in
homozygosity is perinatally lethal, but haploinsuffi-
ciency of the IGF-1 receptor (IGF-1R?/-) resulted in
enhanced stress resistance and lifespan extension by
33% in female, but not male, mice (Holzenberger et al.
2003). Another study conducted independently, found
a lifespan extension of only 4.7% in female IGF-
1R?/- mice, though it confirmed the previously
reported stress resistance (Bokov et al. 2011). In terms
of metabolic phenotypes, the latter study demonstrated
that over ageing the mice developed insulin resistance
and the males glucose intolerance as well. A follow up
study from the Holzenberger lab, demonstrated that
the magnitude of the lifespan extension effect, but not
stress resistance, was depended on genetic background
(Xu et al. 2014). In terms of metabolic phenotypes, the
study corroborated the development of insulin resis-
tance in male mice. Thus, downregulation of IGF-1
signalling does not seem to offer the same beneficial
effects with GH deficiency/resistance. Therefore, GH
deficiency/resistance likely mediates its life extending
effects through mechanisms distinct from IGF-1
deficiency to a large extent.
The neuroendocrine axis of growth control has been
implicated in human ageing as well. GH levels drop
with age, a process known as somatopause. Certain
manifestations of tsomatopause, such as reduction of
muscle mass, causing age-related sarcopenia, and
increase in visceral adiposity are partly reversible by
GH treatment (Rudman et al. 1990). Hence, GH
replacement therapy has been proposed as an anti-
ageing intervention. However, the findings from
research in GH deficient/resistant mouse mutants do
not support such an effect of GH and on the contrary
suggest that such an intervention could have a negative
impact on human ageing (Bartke 2008). Also, in
humans there is an apparent negative correlation
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between height and longevity, thus suggesting a
potential role of GH and IGF-1 regulated growth in
promoting ageing (Samaras and Storms 1992). There
is also genetic evidence implicating the activity of the
somatotropic axis in human ageing. Allele frequency
studies have reported that polymorphic variants of
genes related to GH synthesis, IGF-1 signalling and
insulin action change in frequency with age. Bonafe`
et al. found that allele A of IGF-1R is associated with
low plasma IGF-1 and is more frequent among long-
lived people (Bonafe et al. 2003). Moreover, van
Heemst et al. found that women carrying a SNP
variant of the GH1 gene for human growth hormone
are 2 cm shorter and exhibit a 0.80-fold reduced
mortality (van Heemst et al. 2005). Furthermore,
female offspring of centenarian Ashkenazi Jews were
found to be heterozygous for loss-of-function muta-
tions in the gene encoding IGF-1R (Suh et al. 2008).
However, such evidence is essentially correlative and
it does not reveal the underlying mechanisms of
lifespan extension. Body size per se is not necessarily
a determinant of lifespan extension. Reduced suscep-
tibility to pathologies such as cancer could underlie the
lifespan extending effect in this context (deMagalhaes
and Faragher 2008). This notion is further supported
by the recent report that male carriers of a common
GHR allele lacking exon 3 (d3-GHR) live longer
despite being taller than carriers of the wild-type allele
(Ben-Avraham et al. 2017). Interestingly, a study that
monitored 99 Ecuadorian GH receptor deficient
dwarfs for 22 years, has shown that they were less
susceptible to cancer and obesity, but not long-lived
(Guevara-Aguirre et al. 2011). Therefore, diminished
somatotropic signalling can have beneficial metabolic
effects, even in the absence of lifespan effects in
humans.
Insulin/IGF-1 signalling pathway and metabolic
ageing
During the 1980s and 1990s, mutagenic screen studies
in C. elegans identified the first long-lived mutants,
where single mutations produced large effects on
lifespan. Worms with loss-of-function mutations in
genes in the IIS pathway showed remarkable
increases in mean and maximum lifespan and main-
tained a youthful morphology for longer (Kenyon
2011). Therefore, the IIS pathway was the first
signalling pathway shown to play a pivotal role in
the ageing process. Indeed, loss-of-function mutation
of daf-2, the worm ortholog of the insulin/IGF-1
receptor, resulted in large increases in the lifespan of
worms. In contrast, ubiquitous knock out of the
Insulin Receptor (IR) gene in mice resulted in
neonatal lethality (Accili et al. 1996). Moreover, a
severely diminished IR gene function in humans
causes Dohonue syndrome (leprechaunism) (Kita-
mura et al. 2003). Hence, it was initially thought that
the role of IIS in the regulation of the ageing process
could not be evolutionarily conserved and that the
activity of the IIS pathway was unlikely to promote
ageing in mammals. However, there is now ample
evidence that reduction of the IIS pathway can delay
ageing and improve the metabolic profile of mam-
malian species in late life. The first evidence was
provided from the study of mice with adipose tissue-
specific knockout of the insulin receptor (FIRKO
mice, Fat-specific Insulin Receptor KnockOut).
FIRKO mice were protected against age-related
obesity and exhibited an 18% increase of mean
lifespan in both sexes (Bluher et al. 2003). FIRKO
mice displayed reduced insulin levels and resistance
to age-related glucose intolerance (Bluher et al.
2002). More recently, extension of the maximal
lifespan of heterozygous mice for a ubiquitous null
mutation of the insulin receptor (IR-KO?/-) has been
reported for male, but not female, mice (Nelson et al.
2012). Conversely, reduction of circulating insulin
levels by targeted disruption of insulin genes has
recently been reported to extend lifespan in female,
but not male mice (Templeman et al. 2017). This is an
example of how sex can differentially influence the
effects of genetic interventions even on closely
positioned components of signalling pathways.
Ubiquitous knock-out of the Insulin Receptor
Substrate-1 (IRS1) has also been shown to extend
lifespan (by 32% in females, weaker effect in males)
and improve a wide range of markers of ageing such as
immune and motor system dysfunction and bone and
skin deterioration (Selman et al. 2008, 2011). IRS1
KO mice, although insulin resistant, display improved
glucose tolerance at old age. Although Selman et al.
found no lifespan effects in ubiquitous IRS2 heterozy-
gous knockout mice (IRS2?/-), another study reported
that both ubiquitous IRS2?/- and brain-specific IRS2
KO mice exhibited lifespan extension (Taguchi et al.
2007). Interestingly, ubiquitous IRS2?/- mice were
found to be more insulin sensitive than wild-type
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littermates, but brain-specific IRS2 KO were insulin
resistant and glucose intolerant.
A key effector molecule in IR is PI3K. The
principal IIS-responsive mammalian isoform of
PI3K is p110a (Foukas et al. 2006). Hence, mice
heterozygous for a kinase-dead knock-in mutation in
the gene encoding p110a (p110aKI) displayed insulin
resistance and moderate glucose intolerance at young
age. However, this partial inactivation of PI3K p110a
exerted a protective effect in the long-term so that
aged p110a KI mice were leaner and manifested an
improved metabolic profile compared to their wild-
type littermates (Foukas et al. 2013). These effects
were more prominent in male mice. Consistent with
this, male p110a KI mice showed a modest (approx.
7%) extension in their median lifespan. These findings
are in line with the phenotypes reported for mice with
systemic overexpression of the tumour suppressor
phosphatase and tensin homolog (PTEN), which
counteracts the activity of PI3K. PTEN transgenic
(PTEN-Tg) mice exhibited increased energy expen-
diture, decreased adiposity, improved insulin sensi-
tivity upon high-fat feeding or with aging, and
extended lifespan (Ortega-Molina et al. 2012). High
levels of expression of the uncoupling protein 1
(UCP1) in the brown adipose tissue (BAT) of PTEN
transgenic mice resulted in enhanced nutrient burning
capacity and reduced adiposity and associated
pathologies. All the above evidence supports the
notion that downregulation of the insulin signalling
pathway can have important beneficial metabolic
effects in mammals.
mechanistic Target of Rapamycin (mTOR)
pathway and metabolism
The mTOR signalling pathway is evolutionarily
conserved and integrates nutrient availability, energy
status and growth factor signalling in the control of
cell growth and proliferation. It regulates a multitude
of cellular processes such as mRNA translation,
metabolism, autophagy and stress resistance (Cornu
et al. 2013; Kapahi et al. 2010; Laplante and Sabatini
2012). The mTOR protein kinase is distributed in two
distinct complexes, mTOR Complex 1 and 2
(mTORC1 and 2), each with distinct functions and
substrates. mTORC1 consists of mTOR, mammalian
lethal with sec-13 protein 8 (mLST8, also known as
GbL), and regulatory-associated protein of TOR
(Raptor). Additional components include DEP-do-
main-containing mTOR-interacting protein (DEP-
TOR) and proline-rich Akt substrate 40 kDa
(PRAS40). mTORC1 is acutely sensitive to rapamycin
and regulates ribosomal protein biogenesis, protein
translation and autophagy. mTORC2 is composed of
mTOR, rapamycin-insensitive companion of mTOR
(Rictor), a G protein beta subunit-like associated to
mTOR (mLST8), and stress-activated protein kinase-
interacting protein 1 (mSIN1) (Cornu et al. 2013;
Laplante and Sabatini 2012). S6K1 and 4E-BP1 are
two well-characterised substrates of mTORC1 (Ma
and Blenis 2009), whereas the hydrophobic motif
phosphorylation site (S473) of Akt is a key substrate
for mTORC2 (Sarbassov et al. 2005). Both mTORC1
and mTORC2 are activated by growth factors.
mTORC1 activity is also modulated by availability
of aminoacids and by energy levels through input from
AMPK. Hence, mTORC1 is a central signalling node
that integrates multiple inputs to regulate biological
responses such as protein and lipid synthesis, autop-
hagy and cell cycle progression. mTORC2 has been
implicated in cytoskeletal organisation, cell survival
and metabolism; in the latter to a large extent via its
Akt phosphorylating activity.
Genetic or pharmacological inhibition of mTOR
signalling has been found to extend the lifespan of
invertebrate species including yeast, nematodes, fruit
flies and mice (Kapahi et al. 2010; Lamming et al.
2013). Indeed, deletion of S6K1 protects against diet-
induced obesity, enhances insulin sensitivity and
increases lifespan in mice (Selman et al. 2009; Um
et al. 2004). Moreover mice expressing a hypomorphic
allele of mTOR and mice heterozygous for both
mTOR and mLST8, are also long-lived (Lamming
et al. 2012; Wu et al. 2013). Furthermore, it has
recently been shown that long-lived heterozygous
Akt1 mutants exhibit decreased mTORC1 activity
(Nojima et al. 2013). A role for mTORC2 in the
regulation of lifespan is still largely uncertain, but it
could potentially have an influence through its role as a
modulator of mTORC1 signalling.
The mTOR and IIS pathways are closely linked in
the regulation of energy metabolism and glucose
homeostasis (Zoncu et al. 2011). Early genetic
approaches attempting ubiquitous inactivation of
mTOR in mice resulted in early embryonic lethality
and therefore did not contribute to the study of mTOR
in metabolic regulation (Gangloff et al. 2004;
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Murakami et al. 2004). Hence, tissue-specific muta-
genesis has been applied in order to study the roles of
the two mTOR complexes in metabolic tissues, which
often resulted in disparate metabolic effects depending
on the targeted tissue (Table 1). Tissue-specific dis-
ruption of mTOR signalling pathway components has
been shown to induce differential effects on the
metabolic profile in rodents, summarised in (Polak
and Hall 2009). Deletion of Raptor, a component of
mTOR C1, specifically in the adipose tissue protected
against diet-induced obesity (Polak et al. 2008),
whereas deletion of Raptor in skeletal muscle was
deleterious, causing severe muscular dystrophy (Bent-
zinger et al. 2008). Overexpression of a dominant-
negative version of Raptor in the liver improved
insulin sensitivity (Koketsu et al. 2008), whereas
inhibition of mTOR by rapamycin reduced the
production and release of insulin by pancreatic islets,
leading to hypoinsulinemia and glucose intolerance
(Zahr et al. 2008). Also, aminoacid-induced activation
of mTOR or activation of S6K in the hypothalamus
decreased food intake and body weight (Blouet et al.
2008; Cota et al. 2006). Similar approaches targeting
mTORC2 in the adipose tissue by disruption of the
Rictor gene resulted in larger body mass due to organ
hypertrophy and hyperinsulinemia, but normal glu-
cose tolerance, under standard chow feeding (Cybulski
et al. 2009). These findings have been largely corrob-
orated by another study utilising a similar targeting
approach, with the exception of the glucose tolerance,
which in the later study was found to be impaired
(Kumar et al. 2010). From the above data, it becomes
evident that the effect of downregulation of mTOR
signalling on metabolism is difficult to predict.
Pharmacological inhibition of mTOR with rapamycin
apparently results in negative metabolic effects though
these largely depend on the dosing regimen (see
below). And hypomorphic mTOR expression has no
metabolic phenotypes despite lifespan extension (Wu
et al. 2013). Therefore, in the case of the mTOR
pathway, a relation between body metabolic home-
ostasis and longevity is not obvious.
Insulin sensitivity and longevity
Ageing is associated with a reduction in insulin
sensitivity both in humans and rodents (Basu et al.
2003; Escriva et al. 2007). Age-related insulin
Table 1 Metabolic phenotypes of mTORC1/2 conditionally mutated mice
Component Tissue Metabolic phenotypes References
mTOR Systemic hypomorphic
(mTORD/D mice)
Normal insulin sensitivity and glucose tolerance, and energy expenditure Wu et al.
(2013)
mTOR Skeletal muscle Severe myopathy, increased muscle glucose uptake and glycogen
accumulation, but normal glucose and insulin tolerance
Risson et al.
(2009)
Raptor Adipose tissue Leanness in the face of reduced physical activity and unaffected caloric
intake, protection against diet-induced obesity, improved insulin
sensitivity, elevated energy expenditure due to mitochondrial
uncoupling
Polak et al.
(2008)
Raptor Liver Normal glucose tolerance Lamming
et al.
(2012)
Rictor Liver, liver-specific Rictor
knockout (LiRiKO) mice
Constitutive gluconeogenesis, impaired glycolysis and lipogenesis,
systemic hyperglycemia, hyperinsulinemia, and hypolipidemia
Hagiwara
et al.
(2012)
Rictor Adipose tissue Mice hyperinsulinemic, but glucose tolerant Cybulski
et al.
(2009)
Rictor Adipose tissue Glucose intolerance, marked hyperinsulinemia, insulin resistance in
skeletal muscle and liver and hepatic steatosis
Kumar et al.
(2010)
Rictor Skeletal muscle Glucose intolerance, but increased basal glycogen synthase activity in
muscle
Kumar et al.
(2008)
Mutants for which systemic metabolic phenotypes have been reported
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resistance is thought to be a result of increased visceral
adiposity with age progression. Consistent with this
notion, removal of visceral adipose tissue improves
insulin sensitivity in mice (Gabriely et al. 2002).
Adipose tissue development and function is highly
dependent on sex steroids (White and Tchoukalova
2014) and therefore it is thought that differences in
adipose tissue distribution between sexes would pro-
duce differences in development of insulin resistance,
however there is no clear consensus about this (Kim
and Reaven 2013).
The potential effect of insulin sensitivity on lifes-
pan is still unclear (Barzilai and Ferrucci 2012). In
humans, insulin resistance is accompanied by com-
pensatory hyperinsulinemia and has clearly been
implicated as a risk factor for multiple age-related
diseases. Consistent with this, calorically restricted
rodents and a number of long-lived mice (e.g. GH
deficient/resistant mutants, FIRKO mice, S6K KO
mice) display enhanced insulin sensitivity. However,
as mentioned above, attenuation of the insulin sig-
nalling cascade via genetic inactivation of key IIS
pathway intermediates has been associated with
lifespan extension in model organisms (Kenyon
2010). Moreover, lifespan extension has been reported
in mouse mutants for the IIS or mTOR pathways with
normal (Lamming et al. 2012; Nojima et al. 2013; Wu
et al. 2013) or reduced (Selman et al. 2008; Taguchi
et al. 2007) insulin sensitivity. This implies that
enhanced insulin sensitivity is not a requisite for
extended longevity. However, insulin resistant
mutants, such as IRS1-/- and PI3K p110a KI mice,
display improved glucose tolerance compared to wild-
type littermates at old age (Foukas et al. 2013; Selman
et al. 2008). As mentioned in the Introduction,
hyperglycemia contributes to a large extent to tissue
damage and old age frailty. Therefore, improved glu-
cose tolerance at old age might be a better indicator of
a metabolic effect, which might translate to enhanced
longevity, than insulin sensitivity.
Sirtuins and metabolic effects of sirtuin activation
Sirtuins are a family of nicotinamide adenine dinu-
cleotide (NAD?)-dependent histone deacetylases
(Chang and Guarente 2014; Houtkooper et al. 2012).
There are seven mammalian sirtuins (SIRT1-7) that
differ in their tissue distribution, subcellular
localisation, enzymatic activity and substrate speci-
ficity. In addition to histones, they also deacetylate
transcription factors and other cellular proteins affect-
ing gene expression activity. Their implication in
lifespan regulation emerged when increasing the
dosage of the sirtuin Sir2 was found to extend
replicative lifespan in yeast (Kaeberlein et al. 1999).
Various lines of evidence support the notion that
sirtuins mediate the effects of calorie restriction to a
large extent (Guarente 2011). They have also been
shown to extend the lifespan of worms, flies and mice.
The lifespan extending effects of sirtuin activation
have been disputed, but the improvements in health-
span seem to be robust (Houtkooper et al. 2012).
Sirtuins mediate various beneficial effects on meta-
bolic tissues, such as reduced glycolysis and increased
fatty acid oxidation in liver and muscle, reduced
hepatic lipogenesis, adipose tissue browning and fat
mobilisation (Chang and Guarente 2014). SIRT1, the
principal mammalian sirtuin exerting metabolic
effects, has been shown to be activated via the AMPK
energy sensing pathway in skeletal muscle (Canto
et al. 2010). Therefore, the sirtuin family provides
promising therapeutic targets in metabolic diseases,
such as age-related obesity and diabetes, and a number
of sirtuin activators have been identified or developed.
The natural polyphenol compound resveratrol has
received great attention as a sirtuin activator with
significant beneficial metabolic effects in mice fed a
high-fat diet and in obese humans (Baur et al. 2006;
Lagouge et al. 2006; Timmers et al. 2011). Resvera-
trol’s mechanism of action as a sirtuin activator has
been reported to be indirect, through activation of
energy sensing pathways and modulation of cAMP
and NAD? levels, according to some studies (Park
et al. 2012; Um et al. 2010). However, later studies
demonstrated that the substrate specificity of SIRT1 is
sequence specific thus explaining the lack of activa-
tion by resveratrol against a number of substrates
(Hubbard et al. 2013; Lakshminarasimhan et al. 2013).
A number of synthetic SIRT1 activators have been
developed and tested in preclinical trials (Carafa et al.
2016; Hubbard and Sinclair 2014; Sinclair and Guar-
ente 2014). Moreover, some positive results have been
reported from early stage clinical trials in inflamma-
tory and metabolic disorders (Bonkowski and Sinclair
2016). However, a more detailed evaluation of their
potential for clinical application remains to be seen.
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Pharmacological interventions in healthspan
extension
The demonstration that administration of the mTOR
inhibitor rapamycin late in life can extend the
lifespan of mice was a ground-breaking develop-
ment in the biology of ageing, as it provided solid
proof-of-principle that pharmacological treatment of
ageing is possible (Harrison et al. 2009). It has
boosted efforts to produce pharmacological agents to
improve healthspan by combating age-related dis-
ease. This section summarises evidence supporting a
potential effect of pharmacological agents, known to
modulate the activity of signalling pathways impli-
cated in regulation of healthspan and lifespan, on
metabolic homeostasis. Specifically, the mTOR
pathway inhibitor rapamycin, PI3K inhibitors (IIS
pathway), somatoropic axis inhibitors and metformin
(indirect activator of AMPK) are discussed in more
detail. Sirtuin activators were briefly discussed
above and in more detail in the literature cited
therein.
Rapamycin
Rapamycin acts as an allosteric inhibitor of mTORC1
by forming a gain-of-function complex with the
12 kDa FK506-binding protein (FKBP12). Rapamy-
cin has immunosuppressive and anti-proliferative
properties in mammalian cells. It was approved as an
immuno-suppressant in 1999. In recent years, interest
has focused on the potential of rapamycin and its
analogues (rapalogues) as anticancer drugs (Wander
et al. 2011). Rapamycin has been reported to have both
positive and negative effects on mammal metabolism.
In obesity, the mTOR pathway is hyper-activated in
the adipose tissue thus leading to increased lipogen-
esis, reduced lipolysis and fat accumulation. To limit
its over-activation, mTORC1 blocks insulin signalling
through a S6K-mediated feedback loop destabilising
IRS (Harrington et al. 2004; Shah et al. 2004) and
through direct phosphorylation and stabilisation of
Grb10 (Hsu et al. 2011), provoking an insulin
resistance state. Acute mTOR inhibition through
rapamycin treatment improves insulin sensitivity
in vitro and in vivo by disrupting this negative
feedback loop of insulin signalling (Krebs et al.
2007; Tremblay and Marette 2001). Also rapamycin
protects from diet-induced obesity and prevents
weight gain in mice (Chang et al. 2009a; Makki
et al. 2014). In rats and humans, it reduces age-related
body weight gain when administered 3 times per week
(Rovira et al. 2008). However, glucose intolerance and
insulin resistance have been observed in a few strains
of rodents treated daily with high doses of rapamycin.
In fact, rapamycin increases lipolysis in the adipose
tissue in rats, causing pronounced hyperlipidemia
(Houde et al. 2010). Also, a 2-week rapamycin
treatment aggravates hyperglycemia in a diabetic
mouse model (Fraenkel et al. 2008) and similarly,
rapamycin administration (6 weeks) exacerbates glu-
cose intolerance in diet-induced obese KK/HIJ mice
(Chang et al. 2009b). These controversial findings on
the insurgence of insulin resistance might be explained
by the duration and the doses of rapamycin treatment
(Fang et al. 2013). Rapamycin could therefore still be a
viable pharmacological option to promote beneficial
metabolic effects in humans pending definition of
appropriate dosing regimens.
GH/IGF1 axis inhibitors
Research in a number of GH deficient/resistant mice
as well as in an Ecuadorian human GH receptor-
deficient population, has clearly demonstrated that
downregulation of this pathway exerts beneficial
metabolic effects. Compounds targeting the activity
of the somatotropic axis have been used in the
treatment of acromegaly. Somatostatin analogues
have been used to supress GH secretion, but with
limited efficacy and substantial side-effects (Parkin-
son et al. 2002). Somatostatin inhibits secretion of
insulin and it is therefore unlikely to have beneficial
metabolic and healthspan effects. However, pegviso-
mat, a GH receptor antagonist, has demonstrated
efficacy and an acceptable safety profile (van der
Lely et al. 2012). Beneficial metabolic effects of
short- to medium- term administration of pegvisomat
in type-1 diabetes and acromegaly patients, respec-
tively, have been reported (Lindberg-Larsen et al.
2007; Thankamony et al. 2014). Pegvisomat, is
therefore a compound that could potentially be tested
for healthspan effects upon long-term administration
in humans, although logistic constraints related to
high costs, make it an unlikely candidate as a widely
available therapeutic modality.
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PI3K inhibitors
As discussed above, long-lived IIS mutant mice, such
as IRS1 KO (Selman et al. 2008), PTEN-Tg mice
(Ortega-Molina et al. 2012) and PI3K p110a KI mice
(Foukas et al. 2013) display a metabolic improvement
at old age. Therefore it is reasonable to hypothesise
that use of inhibitors against ‘druggable’ components
of this pathway could represent a strategy in preven-
tion or treatment of metabolic diseases associated with
old age (such as obesity and type-2 diabetes) and in
healthspan extension. A number of inhibitors against
PI3Ks are currently available, mainly through efforts
to target these enzymes in oncology. Proof of principle
that PI3K inhibitors can also be useful in metabolic
disease has been provided by a recent study (Ortega-
Molina et al. 2015). Long-term administration of low
doses of two pharmacological inhibitors of PI3K,
CNIO-PI3Ki and GDC-0941, has been reported to
reduce the adiposity and body weight of obese mice
and rhesus monkeys. The same treatment did not
affect adiposity of mice fed a standard chow. CNIO-
PI3Ki is a small molecule ATP competitive dual
inhibitor of the PI3K isoforms p110a and p110d.
Further testing for isoform specificity, using p110a
and p110d discriminating compounds, revealed that
the anti-obesity effect was particularly prominent
upon inhibition of p110a, the principal insulin
activated isoform, although inhibition of p110d did
contribute to the overall effect (Lopez-Guadamillas
et al. 2016). p110d is highly expressed in leukocytes
and its involvement was possibly due to an anti-
inflammatory effect of p110d inhibition, as inflam-
mation is a well-established contributing factor in
metabolic pathology. These findings suggest that
pharmacological inhibition of PI3K could be an
effective and safe anti-obesity intervention to prevent
or reverse metabolic syndrome in humans.
Metformin
Metformin is a biguanide that has extensively been
used in the treatment of type 2 diabetes. It works by
decreasing glucose production in the liver, augment-
ing glucose utilisation by body tissues and increasing
sensitivity to insulin. Metformin has been used for
more than 60 years, it is safe and has also been
reported to slow aging in C. elegans (Pryor and
Cabreiro 2015). Metformin-treated worms not only
live longer, but also stay healthier for longer (Onken
and Driscoll 2010). Metformin administration
increases the lifespan of mice by nearly 6% and
improves various markers of healthspan (Martin-
Montalvo et al. 2013). Also diabetic patients treated
with metformin live longer than non-treated non-
diabetic control subjects (Bannister et al. 2014).
Therefore, metformin might have substantial benefi-
cial effects on human healthspan. To test this idea,
metformin is set to enter a ground breaking human trial
as a potential anti-aging drug (Barzilai et al. 2016). A
clinical trial called Targeting Aging with Metformin,
or TAME will involve the administration of met-
formin to 3,000 people aged 70–80 years (at roughly
15 centres around the United States), who already have
one or two of three conditions (cancer, heart disease or
dementia) or are at risk of them. The participants will
be monitored to test whether the medication prevents
or delays development of diseases they do not already
have, as well as of diabetes.
Conclusion and perspective
Recent advances in the elucidation of signalling
pathways that modulate the rate of ageing have
made it possible to study the effects of their
manipulation on various pathologies associated with
advanced age in model organisms. However, a
number of confounding factors complicate the
predictions for translational potential of the findings
from model organism to humans (de Magalhaes
2014). Most of the research in the genetics of ageing
and in testing interventions has used inbred animals
with identical genetic backgrounds. Such models do
not reflect the situation of human populations that
are genetically heterogeneous. In many cases,
the responses under investigation have been extre-
mely variable between different strains. A prominent
example is calory restriction in mice, where the
outcome can vary from life extension to life
shortening depending on the genetic background
(Liao et al. 2010). Furthermore, as alluded at various
places above, in many cases, genetic interventions
have stronger or even restricted effects on one sex. It
is conceivable that, as is the case in other diseases,
notably in cancer, in age-related diseases there will
not be a cure suitable for everyone, but treatments
should be personalised based on individual genetics.
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Pharmacologic interventions might have to match
the genetic and epigenetic make-up as well as the
sex of individuals. To this end, continuous advances
in next generation sequencing and human genetics,
together with development of advanced bioinfor-
matic methods, similar to those used to correlate
longevity genes to age-related disease genes and to
drugs (Fernandes et al. 2016), could make it possible
to predict the likelihood of specific interventions to
be effective in combating age-related diseases in
particular individuals.
There is now substantial evidence that pharmaco-
logical interventions in the IIS, mTOR and AMPK
pathways can have beneficial metabolic effects in
mammalian organisms. As discussed above, interven-
tions within these signalling pathways affect meta-
bolic homeostasis, which appears to be a key
determinant of healthspan. A number of compounds
targeting these pathways have demonstrated good
tolerability and substantial beneficial metabolic
effects through preclinical testing in mice (Table 2).
Whether such compounds will only have beneficial
metabolic effects or more generalised healthspan
effects will be of great interest to determine, but it
will certainly be more challenging and it will require
development of suitable biomarkers. Nevertheless, the
application of signalling pathway inhibitors for pre-
vention and treatment of age-related obesity and
insulin resistance seems within grasp based on very
promising results from preclinical stage testing.
Exciting trials are under way to assess the effects of
such compounds, such as the rapamycin trial in pet
dogs (Kaeberlein et al. 2016) and the metformin trial
in humans (Barzilai et al. 2016). Ongoing research in
independent academic laboratories along with larger
scale programmes such as the National Institute of
Aging Intervention Testing Programme (NIA ITP)
(https://www.nia.nih.gov/research/dab/interventions-
testing-program-itp) have made great contributions to
this effort and will likely identify additional com-
pounds with potency to improve healthspan and
lifespan to be subsequently tested in human trials.
These trials hold great promise and a positive outcome
would be a great return for the extensive efforts
invested in research in the field of biology of ageing.
Such developments are eagerly awaited by the
respective scientific community and they are certain to
be welcome by the general public.
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